

## Editorial

### THE RE-ENGINEERING OF A BROAD INTEREST JOURNAL

I am honored to be named the new Editor-in-Chief of *Pharmaceutical Research*, and I have enthusiastically accepted this position as both a personal and professional challenge. I would like to thank the AAPS leadership for its confidence in me to lead the journal to new levels of excellence, and to thank the current associate editors, editorial board members, and the staff at AAPS and Plenum in assisting me during this transition period. In particular, I owe Professor Wolfgang Sadée a debt of gratitude for his sound advice and generosity in personal time in preparing me for this new adventure. The readership owes him a debt of gratitude for his vision in founding the journal and for his devotion to position it to be the leading pharmaceutical journal worldwide.

I have set two goals for the journal. *My first goal is to publish first-rate papers in a timely fashion.* The regional editors in Europe (Professor Bernard Testa) and Japan (Professor Yuichi Sugiyama) and I aim to average 6 months from initial receipt of a manuscript in our offices to publication. In addition to the two regional editors just mentioned, I will be assisted by three associate editors toward reaching this goal. One associate editor will have editorial responsibilities for manuscripts in pharmaco-/socioeconomics and health care policy. The second associate editor will have editorial responsibilities for manuscripts in pharmacokinetics, pharmacodynamics, drug metabolism, clinical science, and drug discovery. And the third associate editor will have editorial responsibilities for manuscripts in drug delivery, preformulation, formulation, and analytical chemistry and biochemistry. In addition, I will work hard with Plenum to identify means to reduce publication time to within 2–3 months from the time of manuscript receipt at its office.

*My second goal for the journal is to diversify its contents.* Presently, the journal publishes a few full-length Research Articles, many Reports, and occasionally Technical Notes. Over time, I plan to add three new sections: (a) *Editorial*

*Commentary*, which will be a brief insightful analysis by an eminent scientist of trends in a given subject area and his/her provocative exposé of future directions in that area; (b) *Reviews*, which essentially will highlight the present state of the science and identify needed work, and will include an extensive reference list; and (c) *Rapid Communications*, which will be high-quality short papers on ground-breaking research and which, therefore, will be moved very rapidly through the system. These are the papers which will be published as is, if accepted.

*Pharmaceutical Research* is at a crossroads. It is facing intensive competition from a number of other pharmaceutical journals worldwide, both for manuscripts and subscriptions. I accept the appointment as Editor-in-Chief with the conviction to ensure that *Pharmaceutical Research* is the premier journal of all of pharmaceutical sciences worldwide and with the expectation that I will succeed in recruiting dedicated associate editors and editorial board members to work diligently toward this goal. I also expect that AAPS and its leadership will continue to recognize the need for leadership in research and respond in kind with resources commensurate with our high level of enthusiasm and devotion. I invite you to continue supporting your journal by submitting your high-quality papers, encouraging your colleagues who have not yet considered *Pharmaceutical Research* to showcase their work to begin doing so, assisting in reviewing manuscripts, and subscribing to the journal.

*Pharmaceutical Research* is your journal; and my associate editors, the editorial board members, and I are very eager to hear from you concerning ways in which the journal can be improved. I hope that I can count on your support, and I pledge to do my best to lead *Pharmaceutical Research* to become a rich source of timely papers on the cutting edge of pharmaceutical sciences worldwide.

Vincent H. L. Lee  
Los Angeles, California, USA